Pozelimab for Paroxysmal Nocturnal Hemoglobinuria (ACCESS 2 Trial)

"The answer is affirmative, according to information on clinicaltrials.gov. This trial was originally posted on March 31st, 2020 and updated most recently on January 8th, 2020. They are looking for a total of 140 patients from 1 site."

"Alexion Pharmaceuticals sponsored the first Pozelimab trial in 2016. That initial study had 270 participants and completed Phase 3 drug approval. To date, there have been 53 trials completed with 30 more currently underway across 265 cities and 45 countries."

"30 trials for Pozelimab are ongoing, with 20 in Phase 3. Trials for this medication are being conducted all over the world, though many of them are based in Bethesda, Maryland. There are a total of 1339 medical sites running these clinical studies."

"Neuromyelitis optica is most commonly treated with Pozelimab, which can also help patients manage hemolysis, thrombotic microangiopathies, and disease activity."

"Pozelimab has undergone multiple rounds of testing and there is some evidence supporting its efficacy, so it received a score of 3."

"Yes, this is an ongoing study that has updated its information as recently as January 28th, 2022. It was first posted on March 31st of the same year. The researchers conducting this trial are looking for a total of 140 patients at 1 location."